米非司酮联合宫瘤消胶囊对子宫肌瘤患者细胞因子和性激素水平影响研究

Effect of mifepristone combined Gongliuxiao on cell factor and sex hormone levels in patients with uterine fibroids

目的：研究米非司酮联合宫瘤消胶囊对子宫肌瘤患者细胞因子和性激素水平影响。方法：选取2013年10月至2014年10月收入我院妇科并存在手术指征的子宫肌瘤患者100例,随机数表分为治疗组和对照组,每组各50例。治疗组使用米非司酮联合宫瘤消胶囊治疗;对照组仅使用米非司酮口服治疗。并对两组疗效、子宫体积、最大肌瘤体积及细胞因子和性激素水平进行比较。结果：治疗组总有效率为94.0%,显著高于对照组的76.0%,组间比较差异有统计学意义（χ^2=6.256,P〈0.05）。治疗前,两组子宫体积及最大肌瘤体积差异无统计学意义（P〉0.05）,治疗后,两组子宫体积及最大肌瘤体积较显著减小,组内比较差异具有统计学意义（P〈0.05）,且治疗组子宫体积及最大肌瘤体积显著小于对照组,差异有统计学意义（P〈0.05）。治疗前,两组血清IL-22,TNF2α水平差异无统计学意义（P〉0.05）,治疗后,与对照组相比治疗组血清IL-22水平显著升高,TNF2α水平显著降低,差异具有统计学意义（P〈0.05）。治疗前两组FSH、LH、E2、P水平比较差异均无统计学意义（P〉0.05）,治疗后两组E2、P水平均显著降低,组内比较差异具有统计学意义（P〈0.05）,治疗后治疗组E2、P水平显著低于对照组,组间比较差异具有统计学意义（P〈0.05）。治疗期间,治疗组4例患者出现潮热,3例患者出现恶心呕吐,无其他不良反应;对照组6例患者出现潮热,5例患者出现恶心呕吐,无其他不良反应,两组不良反应较轻,未影响治疗,治疗结束后恢复,治疗前后两组均检查血常规及肝肾功能,无异常,两组不良反应发生率无无统计学差异（χ-2=1.118,P〉0.05）。结论：米非司酮联合宫瘤消胶囊治疗子宫肌瘤效果较好,并可调节患者内分泌功能,不良反应发生率低,值得临床推广应用。

Objectives：To investigate the effect of mifepristone combined Gongliuxiao on cell factor and sex hormone levels in patients with uterine fibroids.Methods：100 patients with uterine fibroids were randomly divided into treatment group and control group,50 cases in each group.Treatment group was treated with mifepristone combined with Gongliuxiao capsule;the control group was given mifepristone.The effect,uterine volume,maximum fibroid volume and cell factor and sex hormone levels were evaluated.Results：The total effective rate of treatment group was 94%,significantly higher than 76% in the control group,with significant differences between the groups （χ^2= 6.256,P〈0.05）.Before treatment,the two groups had no statistically significant difference in uterine volume and maximum fibroid volume （P〉0.05）,but after treatment,the uterine volume and maximum fibroid volume was significantly decreased in both groups,with statistically significant difference within the group （P〈0.05） and in the treatment group,the uterine volume and maximum fibroid volume was significantly less than the control group,with statistically significant difference （P〈0.05）.Before treatment,the Serum IL-22 and TNF2α levels in the two groups was not significantly different （P〉0.05）;after treatment,compared with the control group,the serum IL-22 level of the treatment group was significantly increased,and TNF2α levels decreased significantly,with statistically significant difference （P〈0.05）.Before treatment,the FSH,LH,E2,P levels in the two groups were not significantly different （P〉0.05）;E2 and P levels in the two groups after treatment significantly decreased,with statistically significant difference within the group （P〈0.05）,and those in the treatment group was significantly lower than the control group,with statistically significant difference （P〈0.05）.During the treatment,there were 4 patients with fever,3 patients with nausea and vomiting in the treatment group;there were 6 patients with fever and 5 patients with nausea and vomiting in the control group.All the adverse reactions were mild,which did not affect recovery.The blood and liver function were checked both before and after treatment,with no abnormal situation found.No statistical difference was found in adverse reactions between the two groups （χ^2= 1.118,P〉0.05）.Conclusion：The treatment of mifepristone,combined Gongliuxiao in patients with uterine fibroids is effective,which can be applied in clinical practice.